Introduction
Peripheral arterial disease (PAD) threatens the survival of extremity (appendages, usually legs, feet, and toes) and often causes lifelong disablement. 1 The incidence of PAD in the USA is estimated at over 300 000 new patients per year, and the prognosis for many of these patients is poor. Intermittent claudication (muscle pain) affects more than 5% of people over 50 years of age and has a variable outcome with symptoms progressing rapidly in 25% of patients and almost 10% requiring amputations within 5 years. Progressive deterioration to rest pain or gangrene occurs in about 20% of all patients with intermittent claudication. The life expectancy of amputees is less than 5 years. PAD is treated conventionally by surgical reconstruction and peripheral transluminal angioplasty. The rate of restenosis is high and more than 150 000 lower limb amputations are performed annually in the United States. 2 Preclinical studies using animal models of PAD have demonstrated the efficacy and safety of proteins, plasmid, and adenoviral vectors delivering vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) by vascular infusion or intramuscular injection (reviewed in Webster 3, 4 ). The most commonly used animal model is the rabbit hindlimb, made ischemic by excision of the femoral artery. 5 Early studies demonstrating angiogenesis and improved collateral flow with recombinant proteins were subsequently reproduced with plasmids and adenovirus expressing the genes for VEGF and FGF. 3, 4, 6, 7 In most of these studies, vascular changes were reported only at relatively early follow-up times, 60 days or less after gene delivery. Two pilot clinical trials of Ad-VEGF demonstrated safety and suggested a small but encouraging efficacy. 8, 9 These pilot studies supported the implementation of a larger phase II double-blind, randomized, placebo-controlled trial involving 135 subjects. 10 Follow-up studies from the latter measuring ankle-brachial ratios and peak-walking times at 12 and 26 weeks indicated no difference between treatment and placebo. The study concluded that intramuscular delivery of adenovirus encoding VEGF121 was not an appropriate treatment strategy for patients with unilateral PAD.
One of the problems of gene transfer to tissues with plasmid and adenoviral vectors is the transitory nature of expression of the transgene. Adenoviral vectors typically express within the first week of transfer and expression declines to basal level during the second week. Plasmid transfer is less efficient but may express for a longer period. 5 There has been ongoing debate as to whether the short burst of VEGF obtained by adenoviral vectors is sufficient to support the production of stable mature collateral vessels. One possibility is that a transitory increase of expression is sufficient to initiate the process, and vessels will grow and mature in response to a cascade reaction that includes the induction of endogenous angiogenic factors to sustain maturation. The other possibility is that vessel development requires continued production of the initiating factors (VEGF and FGF) and premature withdrawal will result in regression. We present here evidence to support the latter possibility. Ad-VEGF delivery to ischemic hindlimb muscles resulted in an early burst of angiogenesis that coincided with peak VEGF expression but was not sustained. The high rate of endothelial activation caused by elevated VEGF was accompanied by a parallel increase of nuclear condensation and fragmentation indicative of apoptosis.
Results
Serum VEGF level following the injection of 1 Â 10 10 PFU VEGF165 at time zero is shown in Figure 1 . The level peaked within 2 days, decreased significantly by week 1 and returned to baseline within 3 weeks. These kinetics are consistent with the known transient nature of gene expression following delivery with adenovirus and are similar to other reports of serum VEGF after gene delivery. 11, 12 Serum VEGF did not increase in control ischemic animals, but tissue levels of the RNAs of both VEGF and metallothionein (a hypoxia-activated gene 13 ) increased at 8, 24, and 48 h after imposition of ischemia, determined by Northern blot analysis (data not shown).
The transient nature of transgene expression from adenoviral vectors is due in part to neutralization by cytotoxic T lymphocytes; it is also possible that human VEGF may induce a neutralizing humoral response in rabbit.
Representative angiograms at all time points after surgery including Ad-VEGF treatments or controls (saline) are shown in Figure 2 . No differences were apparent between treatment and control at 2 days, but Ad-VEGF treatments displayed visibly more contrast at 1 and 3 weeks. These differences were dissipated at later times. Additional controls were run to determine the effects of control adenovirus injections at 2 days and 1 week. Replication-defective Ad-5 (1 Â 10 10 PFU) containing the luciferase cDNA (Ad-cytomegalovirus (CMV)-Luc) was injected into the ischemic hindlimbs of four rabbits and angiography was repeated at 2 days and 1 week. There were no detectable differences between the angiograms from controls injected with Ad-CMV-Luc or PBS (data not shown). Figure 3 shows quantitation of vessel density (angiographic score (A)), peak vessel intensity, indicative of maximal flow capacity (B), and contrast transition time, inversely related to blood flow (C) (see Materials and methods). By these analyses, the treated animals had more large arteries, higher capacity, and increased flow rate compared with the control group at 1 week (P ¼ 0.0043, 0.09, and 0.001, respectively). Although this trend appeared to be maintained, the values were not significant at any of the later time points.
Angiographic 'blush' occurs as a late event during infusion of contrast medium and is considered to represent capillaries too small to be resolved as distinct vessels or leakage of contrast medium into the interstitial space. 6, 14 Representative angiograms showing the blush at each time point are shown in Figure 4 and quantitative data are shown in Figure 5 . The total amount of contrast in the blush is indicated by the peak of the time-intensity curves ( Figure 5 ). As expected, the decrease of the peak intensity following ischemia is extremely significant (Po0.0001), indicating that there is very little blush after surgery, and there was no significant change after 2 days (not shown). At 1 week, the peak intensity was significantly larger for the treated versus the control animals (P ¼ 0.009). Again, although this trend was apparent at each remaining time point, the differences were not significant from controls after 1 week.
These results suggest that collateral vessels are produced in the Ad-VEGF-treated muscles during the first week. Presumably, this may involve capillaries that establish reconnections between large vessels and allow temporarily improved flow compared with controls at 1 week. To investigate histological changes, muscle samples from the hindlimbs of treated and untreated animals at each time point were immunostained with anti-Ki67 and CD31 antibodies to identify cycling nuclei and total endothelium, respectively. Representative fields of Ki67 immunostained muscle are shown in Figure 6a and quantitation from 10 fields (41000 nuclei) from different areas of the adductor muscle is shown in Figure  6b . Ki67-positive nuclei in both treated and untreated muscles were significantly increased at 2 days and 1 week and returned to baseline levels at all later times. In the 2-day treated samples, more than 30% of nuclei were Ki-67 positive; these positive nuclei were distributed throughout the muscle with patchy areas of even higher Adenoviral-VEGF-mediated angiogenesis MJ Gounis et al densities (up to 60%) often associated with larger vessels (latter data not shown). This early activation of endothelial nuclear cycling in the Ad-VEGF-treated muscles coincides closely with serum VEGF (Figure 1 ). Vessel densities, determined by CD-31 immunostaining and hematoxylin counterstain, are shown in Figure  7a and b. The density of nuclei in the muscle border regions was significantly increased at 2 days in both treated and untreated muscles compared with controls, and the treated samples had significantly more nuclei than the untreated. Ad-VEGF-treated groups at 2 days and 1 week were characterized by regions where the nuclei were at very high density, interspersed with a normal, lower density pattern. In control muscle (and in all samples from 3 to 13 weeks), muscle fibers were typically associated with 2-4 peripheral nuclei, but in the dense regions of 2-day VEGF-treated muscles there were as many as 20 nuclei associated with each muscle fiber. Endothelial nuclear densities declined in all samples after 2 days, but there was a trend towards higher density in the treated muscles at all times.
Endothelial cell apoptosis was estimated by TUNEL and Hoechst 33258 staining as described in Materials and methods. Representative fields at 2 days are shown in Figure 8a . Hoechst-stained nuclei in the untreated samples appeared as smooth-edged oval structures typical of normal nuclei. In contrast, there were multiple condensed and fragmented nuclei in the Ad-VEGFtreated samples (arrowheads in Figure 8 , panel e). Figure  8 , panel f shows a typical field of TUNEL staining in a region of high-density endothelial nuclei from the 2-day Ad-CMV-VEGF treatment group. The clusters of TUNEL-positive nuclei shown were only observed in the VEGF-treated tissues (compare panels f and c). TUNELpositive nuclei at lower density were identified in most regions in the 2-day-treated samples, but dropped to o10% of the maximum after 1 week (data not shown). TUNEL-positive nuclei were rarely seen in untreated tissue samples (data not shown). Quantitation of Hoechst-positive nuclei by scoring 41000 nuclei per sample indicated 6.3% condensed and fragmented nuclei in 2-day-VEGF-treated muscles. In all other samples this was less than 1%.
Discussion
Our results provide the following new information with respect to Ad-VEGF-mediated therapeutic angiogenesis in the ischemic hindlimb: (1) Cell cycle of endothelial The combined information from angiography and immunostaining suggests that the following sequence of events takes place in the rabbit hindlimb model of PAD following Ad-VEGF treatment. Femoral artery surgery to initiate ischemia causes hypoxia and possibly inflammation in the muscles (of treated and untreated groups) distal to the severed artery. In the nontreated muscles, VEGF is moderately induced and (possibly in concert with the pro-angiogenic environment mediated by hypoxia) is responsible for an early activation of endothelial cells. Endothelial cell proliferation takes place in both treated and untreated muscles, but is more pronounced in the treated muscles. Treated muscles displayed almost 10-fold more Ki67-positive nuclei than untreated muscle at the peak of VEGF expression (2-3 days). At this stage, there was only moderate angiographic evidence of revascularization in either treated or untreated muscles. The largest improvements in angiographic parameters and the greatest difference between control and treated muscles occurred at 1 week. Paradoxically, at this stage, the numbers of Ki67 and serum-VEGF level decreased close to baseline values. Although tissue VEGF levels may be sustained longer than the serum levels because of receptor binding, previous studies have indicated that peak expression even in the muscle occurs as early as 24 h after adenoviral gene delivery of VEGF. 15 The gain in angiographic parameters at 1 week is most likely due to the establishment of new connections between perfusion vessels in the nonischemic border muscle and pre-existing vessels in the ischemic region. This process occurred more rapidly in the treatment groups reflecting the greater activation of endothelial cells. Importantly, Ad-CMV-VEGF treatment mediated a 1.6-fold improvement in perfusion at 1 week compared with controls (Po0.01; Figure 3c ).
In agreement with previous reports (see Hoefer et al 16 ), angiography indicated that control muscles undergo a progressive return to normal perfusion by growing collateral vessels without a significant angiographic blush. In our studies, none of the angiographic parameters from control and treated muscles were significantly different after 1 week. The enhanced blush in the treatment groups at 1 week coincided with an increase of vessel density, measured by immunohistology. Therefore, the 1-week blush represents contrast in capillaries possibly with a component of extravasation due to contrast leakage from unstable vessels. It is not possible to distinguish quantitatively between these two possibilities; contrast perfusion in the blush washed out very rapidly, consistent with most of it being intravascular (data not shown). Excessive extravasation of contrast is expected to wash out more slowly. Both phenomena may reflect disorganized or incomplete growth of microcapillaries that is a result of high-level transient VEGF expression. The magnitude of blush gradually reduced as the profiles of treated and control muscles converged. A similar dense network of microcapillaries was reported in human hearts injected with b-FGF. 17 Our results are consistent with most previous reports on the effects of Ad-VEGF in preclinical studies using animal models of PAD. Gowdak et al 18 reported significantly higher vascular densities in rabbit hindlimb muscles injected with plasmid encoded VEGF at 1 week but not 2 weeks after treatment. Vajanto et al 11 reported an early transient increase of serum VEGF by 2 Â 10 10 PFU adenovirus in the rabbit hindlimb and significantly increased capillary density at 30 days. In the latter study, Ad-lacZ also significantly stimulated capillary density and it is not clear whether the angiogenesis was attributed to VEGF or the consequences of viral infection. Hershey et al, 12 studying a lower dose of Ad-VEGF (1 Â 10 9 PFU) in the rabbit, confirmed an early transient VEGF expression and (a) Large artery density is determined by the number of pixels contained in a masked region common to all angiograms by reference to the femur; it corresponds to arteries with diameters 4250 mm (b). Peak image intensity quantifies the total amount of contrast that enters the large arteries and represents perfusion. (c) The transition time measures the time to peak intensity and is inversely related to regional blood flow. Methods of quantitation are described in detail in Sadasivan et al 27 and Lieber et al. 28 The treated animals had more large arteries, higher capacity, and increased flow rate compared with control group at 1 week (P ¼ 0.0043, 0.09, and 0.001, respectively; n ¼ 7 for each).
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demonstrated increased capillaries at 4 weeks compared to nonischemic controls, but no improvement in blood flow. Mack et al 19 injected Ad-VEGF into ischemic rat hindlimbs and reported a three-fold improvement in vascular score by angiography, but only about 1.5-fold increase in vessel density by histology 3 weeks after treatment.
Although pilot clinical trials of Ad-VEGF121 demonstrated safety and a promise of efficacy, 8, 9 the negative results from the larger RAVE trial have dampened enthusiasm for VEGF and, in particular, Ad-VEGF as a sole therapy for critical limb ischemia or claudication. 10 The RAVE trial was a randomized, double-blind, placebo-controlled trial involving 135 patients with disabling intermittent claudication that received singleor double-dose Ad-VEGF121. The study reported no difference between treatment and placebo for any of the endpoint parameters. Our results taken with other animal studies offer two reasons for the failure of Ad-VEGF to produce a therapeutic benefit. (1) The period of VEGF expression is too short to support stable vessels. This possibility is also supported by the work of Dor et al, 20 where it was shown that the premature withdrawal of VEGF expression in the heart or liver of transgenic mice also resulted in regression of newly formed vessels. (2) Global delivery of VEGF to all regions of muscle rather than to defined ischemic regions may be expected to promote disorganized growth of vessels. Collateral vessel production during ischemia is thought to involve VEGF production by hypoxic cells within the 
Control Treated
Peak Blush Intensity ** Figure 5 Peak blush intensity, quantifies the maximum amount of contrast that enters into the microvasculature as determined by mathematical modeling of angiographic blush intensity histories. Peak blush is related to the microvascular density and possibly extravasalation of contrast. Difference from sham is significant at 1 week (Po0.01; n ¼ 12).
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ischemic tissue. 21 Diffusion of VEGF out from the hypoxic source may provide critical directional cues for new vessels to grow into the ischemic region. These cues are likely to be missing in most experimental models of therapeutic angiogenesis and in clinical trials of VEGF therapy because there is no targeting or regulation of the VEGF transgene (also supported by Dor et al 20 ) . It seems possible that sustained expression of VEGF, possibly using an AAV delivery system with VEGF expression regulated by a hypoxia (HIF-1) responsive promoter, will promote stable conducting vessels. 4, 22 Indeed, a recent report indicated that sustained VEGF expression supported by AAV-mediated delivery induced arteriogenesis in the rat hindlimb. 23 In conclusion, angiogenesis in the ischemic hindlimb in response to Ad-VEGF injection is confined to the period of VEGF expression that occurs in the first week of gene delivery. The response involves a powerful activation of endothelial cells that promotes angiographically distinct vessels at 1 week. The angiogenic blush that develops in treated but not untreated muscles may represent disorganized capillary growth by a stimulus that is transient and lacks directional cues. After the first week, both large vessels and the blush decline so that Adenoviral-VEGF-mediated angiogenesis MJ Gounis et al within 3 weeks there is no significant difference between treated and untreated muscles. Therefore, Ad-VEGF treatment initiates transient angiogenesis associated with transient VEGF expression. This may explain why most clinical trials have been disappointing. We propose that this may be resolved by using a permanent AAV or Lentiviral vector with a promoter directing hypoxiaregulated VEGF expression.
24,22
Materials and methods
Adenovirus
Replication-defective adenovirus serotype 5 expressing the human VEGF165 cDNA, including the signal sequence for secretion and under the direction of the CMV promoter (Ad-CMV-VEGF165), was a generous gift from Dr MC Capogrossi (Laboratorio di Patologia Vascolare, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy). The construction of Ad-CMV-VEGF165 has been reported previously; 25 expression of the construct and secretion of VEGF were confirmed by infecting HeLa cells with 60 PFU/cell of Ad-CMV-VEGF165 and measuring VEGF by ELISA (R&D Systems, Minneapolis, MN, USA) in cell lysates and culture medium at intervals after infection. Secreted VEGF accumulated to 4200 pg/ 10 6 cells after 48 h and more than 95% of the VEGF was secreted (data not shown). This is consistent with previous reports using this construct. 25, 26 Adenovirus expressing the luciferase cDNA (Ad-CMV-Luc) was obtained from the Vector Core facility, Molecular Medicine Institute, University of Pittsburgh. At least 1000 nuclei in the muscle border regions of at least two muscle samples in each case were counted for each condition. Nuclear density was significantly higher than controls in both 2-day and 1-week samples (Po0.02).
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Animal model
Ischemia in the hindlimb of New Zealand White rabbits was implemented as described previously. 16, 19 All procedures were approved by the Institutional Animal Care and Use Committee of the University of Miami. Briefly, under gas anesthesia and sterile conditions, a midline incision was made on the medial thigh of one hindlimb. The iliac and femoral arteries were exposed and ligatures attached on the external iliac artery at the level of the inguinal ligament and a segment of the femoral artery. 
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The femoral artery between the ligatures was dissected and removed. Angiography was performed before and after surgery as described below. Excision of the femoral artery may result in retrograde thrombus propagation to the origin of the external iliac artery; therefore, blood supply to the limb is immediately restricted to flow through the internal iliac artery and any associated collateral vessels. At 30 min after femoral incision, the thigh muscles were injected with 1 Â 10 10 PFU of Ad-CMV-VEGF165, 1 Â 10 10 PFU Ad-CMV-Luc, or 1 ml of saline as the control. In preliminary experiments, we tested a range of adenoviral doses including 1 Â 10 9 , 1 Â 10 10 , and 2 Â 10
10
. The dose of 1 Â 10 10 was found to generate more angiographically distinguishable vessels than the lower dose at 1 week and did not cause measurable edema at 2 days, 1 week or 3 weeks (data not shown). The latter observation is in contrast with a previous report that 1 Â 10 9 PFU of Ad-CMV-VEGF165 caused significant edema of the hindlimb. 12 We can only attribute this to differences in the animal models. Adenovirus was delivered directly into the adductor muscle in a total volume of 1 ml at eight injection sites on each side and distal to the excised region of the femoral artery. After gene delivery, the incision was closed and rabbits received analgesics and antibiotics.
Study design
The study included 53 rabbits operated for unilateral hindlimb ischemia as described above. In all, 27 rabbits received Ad-VEGF165 in PBS at the time of surgery and 26 received only PBS. Angiography was performed on all animals before and after surgery and the angiography was repeated before killing. Ad-VEGF-treated and untreated animals were killed at 2 days (n ¼ 2), 1 week (n ¼ 12), 3 weeks (n ¼ 14), 6 weeks (n ¼ 12), and 13 weeks (n ¼ 13) after surgery. Blood samples were collected after 2 days, and 1, 2, 3, and 6 weeks. Hndlimbs were examined for evidence of edema immediately after killing and dissected for immunostaining and TUNEL analysis.
Angiography
Angiographic sequences were acquired before and after surgical induction of ischemia, and at the follow-up point in each animal. These methods have been described previously. 27, 28 Briefly, a catheter was positioned in the descending aorta via a trans-carotid approach. Injections of 5 cc of Visipaque 320 s (Amercontrol Health, Buckingshire, UK) at a rate of 3 cc/s were performed using a custom-made automated injector system. This injector system has an accuracy of Â 0.25 ml. Injection pressures were monitored in order to ensure repeatability. Images of the limbs were acquired at a rate of 30 frames/s. Throughout each procedure, imaging and injection parameters were precisely controlled. Images were processed, and the time-intensity data extracted from the arteries having a diameter greater than 250 mm were modeled mathematically. Prior to extracting intensity data from the images, an elliptical region of interest was established for each case, with its orientation and size being a function of the femur. This region of interest forms a consistent window of observation providing impartial analysis. Using threshold image-processing methods, the large arteries were isolated and analysis was performed for vessels having diameters greater than 250 mm. These data were modeled, and the model parameters provided indices quantifying the regional blood flow and large artery density. By inverting these images, the contribution of the microvasculature within the elliptical window could be analyzed separately. The time-intensity data from the angiographic blush, meaning the attenuation of X-rays due to contrast transport within the microvasculature, were also quantitated. From the analysis of the angiographic blush, the relative densities of the microvessels were determined by the amplification factor of the mathematical model. The effect of maximum vasodilation on the blush parameter was examined by infusion of nitroglycerine (100 mg/kg) into 1-week-treated and untreated animals. Nitroglycerine did not affect the level of blush in either subject (data not shown).
ELISA, TUNEL and immunostaining
Venous blood samples were obtained at 2 days, 1 week, 3 weeks, and 6 weeks. Red cells were removed by centrifuging at 41C and the levels of human VEGF were measured using an enzyme-linked immunoabsorbent assay (ELISA) as described by the manufacturer (R&D Systems, Minneapolis, MN, USA). Immediately after killing, the hindlimbs were dissected and 3 Â 1 cm 2 transverse sections of muscle tissues underlying the femoral artery were taken and snap frozen in OCT compound, followed by standard fixation in formalin and paraffin embedding. Serial tissue sections were stained with antibodies against CD31 or Ki67 to identify endothelial cells and cycling cells, respectively, and counterstained with hematoxylin to identify nuclei. Hoechst 33258 staining, quantitation of condensed nuclei, and TUNEL on the same sections were carried out as described previously. 29, 30 Capillary density was determined by counting the number of intermyofilament CD-31-positive nuclei in multiple fields of muscle sections from at least two animals per time point. The fraction of Ki67-positive or apoptotic nuclei was calculated by counting at least 1000 nuclei per sample per time point. All microscopy was implemented using a Zeiss Axiovert 200 fluorescent microscope with Â 40 objective and AxioVision 4 software.
